GlaxoSmithKline Pharmaceuticals Limited

NSE:GLAXO India Drug Manufacturers - General
Market Cap
$4.90 Billion
₹424.26 Billion INR
Market Cap Rank
#6601 Global
#234 in India
Share Price
₹2504.40
Change (1 day)
+0.74%
52-Week Range
₹2272.60 - ₹3466.20
All Time High
₹3466.20
About

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal disease… Read more

GlaxoSmithKline Pharmaceuticals Limited - Asset Resilience Ratio

Latest as of September 2025: 35.83%

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) has an Asset Resilience Ratio of 35.83% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
₹13.13 Billion
Cash + Short-term Investments
Total Assets
₹36.65 Billion
All company assets
Resilience Assessment
Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how GlaxoSmithKline Pharmaceuticals Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down GlaxoSmithKline Pharmaceuticals Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₹0.00 0%
Short-term Investments ₹13.13 Billion 35.83%
Total Liquid Assets ₹13.13 Billion 35.83%

Asset Resilience Insights

  • Very High Liquidity: GlaxoSmithKline Pharmaceuticals Limited maintains exceptional liquid asset reserves at 35.83% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

GlaxoSmithKline Pharmaceuticals Limited Industry Peers by Asset Resilience Ratio

Compare GlaxoSmithKline Pharmaceuticals Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Novartis AG
PINK:NVSEF
Drug Manufacturers - General 0.13%
Pfizer Inc
NYSE:PFE
Drug Manufacturers - General 7.18%
AbbVie Inc
NYSE:ABBV
Drug Manufacturers - General 0.02%
Biogen Inc
NASDAQ:BIIB
Drug Manufacturers - General 2.74%
Zhejiang Int'L Group Co Ltd
SHE:000411
Drug Manufacturers - General 0.00%
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
Drug Manufacturers - General 5.75%
Hunan Jingfeng Pharmaceutical
SHE:000908
Drug Manufacturers - General 0.38%
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
Drug Manufacturers - General 5.37%

Annual Asset Resilience Ratio for GlaxoSmithKline Pharmaceuticals Limited (2014–2025)

The table below shows the annual Asset Resilience Ratio data for GlaxoSmithKline Pharmaceuticals Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 47.69% ₹19.59 Billion ₹41.08 Billion -2.71pp
2024-03-31 50.40% ₹17.93 Billion ₹35.57 Billion +1.73pp
2023-03-31 48.67% ₹16.19 Billion ₹33.27 Billion -6.25pp
2022-03-31 54.92% ₹25.45 Billion ₹46.33 Billion +31.41pp
2021-03-31 23.51% ₹7.32 Billion ₹31.13 Billion -7.01pp
2020-03-31 30.52% ₹9.57 Billion ₹31.36 Billion +3.70pp
2019-03-31 26.82% ₹10.49 Billion ₹39.11 Billion +37.26pp
2018-03-31 -10.44% ₹-4.12 Billion ₹39.47 Billion -35.98pp
2017-03-31 25.54% ₹7.67 Billion ₹30.04 Billion -15.56pp
2016-03-31 41.10% ₹12.52 Billion ₹30.46 Billion -15.96pp
2015-03-31 57.06% ₹18.40 Billion ₹32.24 Billion +56.74pp
2014-03-31 0.32% ₹100.03 Million ₹31.30 Billion --
pp = percentage points